SALT LAKE CITY, March 07, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will participate in the 36th Annual ROTH Conference being held March 18-19, 2024.
Presentation
Date: March 18, 2024
Location: The Ritz Carlton Laguna Niguel in Dana Point, California
Time of Presentation: 8:00 a.m. PST
Format: Fireside chat
A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register online to view the webcast here: https://wsw.com/webcast/roth48/clene/1959711.
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
Contacts:
| Media Contact Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC This email address is being protected from spambots. You need JavaScript enabled to view it. This email address is being protected from spambots. You need JavaScript enabled to view it. (858) 717-2310 | Investor Contact Kevin Gardner LifeSci Advisors This email address is being protected from spambots. You need JavaScript enabled to view it. 617-283-2856 |
| Last Trade: | US$0.34 |
| Daily Change: | -0.0065 -1.88 |
| Daily Volume: | 116,348 |
| Market Cap: | US$43.670M |
February 29, 2024 February 22, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MORE
